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OBJECTIVES This study investigated the effect of reducing serum lipids on carotid artery intima-media
thickness (IMT) in asymptomatic patients with hypercholesterolemia from Fukuoka, Japan.
BACKGROUND Carotid atherosclerosis is a strong, independent predictor of morbidity and mortality in
patients with coronary heart disease (CHD).
METHODS A total of 246 asymptomatic hypercholesterolemic patients (mean age 66 years) were
randomized to receive either probucol (500 mg/day, n  82) or pravastatin (10 mg/day, n 
83) or to enter a control group (diet alone, n  81); they were followed for two years. The
change in IMT in the common carotid artery was the primary end point measure, and the
incidence of major cardiovascular events was the secondary measure.
RESULTS Over the two-year period, serum low-density lipoprotein (LDL) cholesterol was significantly
reduced in the pravastatin group (36%), the probucol group (29%) and the control group
(12%) (p 0.0001, p 0.0001 and p 0.05, respectively). After two years, the probucol and
pravastatin groups showed a significant reduction in IMT (13.9% and 13.9% and p 
0.01 and p  0.01, respectively), but there was significant IMT thickening (23.2%; p 0.05)
in the control group. Probucol reduced the rate of IMT increase, independently of its
reduction of LDL or high-density lipoprotein cholesterol. Moreover, there was a significantly
lower incidence of cardiac events in the probucol group (2.4%) than in the control group
(13.6%) (p  0.0136).
CONCLUSIONS Probucol reduced cholesterol levels and stabilized plaque, leading to a lower incidence of
cardiac events in these hypercholesterolemic patients. (J Am Coll Cardiol 2002;39:610–6)
© 2002 by the American College of Cardiology
Overwhelming evidence from epidemiologic and clinical
studies (1) has demonstrated that low-density lipoprotein
(LDL) cholesterol is a key element in the development of
atherosclerosis, and that reducing LDL cholesterol levels
leads to a lowered risk of coronary heart disease (CHD).
Carotid atherosclerosis is a strong independent predictor of
morbidity and mortality in patients with CHD (2). High
plasma total LDL cholesterol concentrations are associated
with an increased prevalence of carotid atherosclerosis, and
drug therapy to reduce LDL cholesterol has been shown to
decrease the extent of carotid atherosclerosis (3).
Measurement of the carotid artery intima-media thick-
ness (IMT) by high-resolution B-mode ultrasonography has
previously been used for the noninvasive detection of early
carotid atherosclerosis. The IMT is also a reliable end point
for intervention trials assessing disease progression. Further-
more, ultrasonography can directly quantify early athero-
sclerotic changes and the response to risk factor modifica-
tion. In addition, the measurement of carotid artery IMT by
high-resolution ultrasound shows less variability than that
with angiographic measurement of the carotid arteries (4),
so a smaller sample size is required to determine the benefits
of treatment or to accurately assess the presence of early
atherosclerosis.
Development of the 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors (statins) has led to the wide-
spread use of lipid-lowering drugs. The clinical benefit of
statins for primary and secondary prevention of the cardio-
vascular complications of atherosclerosis, especially in asso-
ciation with coronary artery disease, has been investigated in
several large clinical trials (5). The Kuopio Atherosclerosis
Prevention Study (6) and the Carotid Atherosclerosis Ital-
ian Ultrasound Study (7) have recently evaluated the effect
of pravastatin on carotid atherosclerosis, as measured by
B-mode ultrasonography. Both studies showed a significant
reduction in the rate of carotid artery IMT progression
(6,7).
Probucol, 4,4-(isopropylidenedithio) bis(2,6-di-tert-
butylphenol), has been reported to prevent atherogenesis by
acting as an antioxidant and suppressing the oxidative
modification of LDL, in addition to its recognized action in
lowering cholesterol levels (8). It has been shown to cause
marked regression of cutaneous (9) and tendon (10) xan-
From the Departments of *General Medicinel , and †Medical Informatics, Kyushu
University Hospital and ‡National Kyushu Medical Center, Fukuoka, Japan. This
study was supported by a grant from the Japanese Ministry of Education, Science, and
Culture, Tokyo, Japan.
Manuscript received April 3, 2001; revised manuscript received November 5, 2001,
accepted November 16, 2001.
Journal of the American College of Cardiology Vol. 39, No. 4, 2002
© 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(01)01783-1
thomas in familial hypercholesterolemia. Retardation of the
progression of coronary (11) and femoral (12) atherosclero-
sis has been related to a decrease of LDL cholesterol and an
increase of high-density lipoprotein (HDL) cholesterol
levels, in agreement with the general concept of the role of
HDL in reverse cholesterol transport (13). Because probu-
col is known to decrease HDL cholesterol, it seems impor-
tant to study the effect of this drug on atherosclerosis.
The aim of the present study was to determine whether
treatment of hypercholesterolemic patients with probucol or
pravastatin could retard the progression and promote the
regression of carotid atherosclerosis, by measuring the effect
of two years of treatment with probucol or pravastatin on
carotid artery IMT in hypercholesterolemic patients. To the
best of our knowledge, this is the first study to use B-mode
ultrasonography to compare the effects of probucol and
pravastatin on carotid atherosclerosis.
METHODS
Study group. Between February 1996 and February 2000,
asymptomatic hypercholesterolemic patients who met the
following criteria were eligible to be enrolled in the study: 1)
primary hypercholesterolemia (defined as a serum total
cholesterol level of at least 220 mg/dl); and 2) treatment
with either probucol or pravastatin. A total of 246 Japanese
patients between the ages of 30 and 89 years were enrolled.
Exclusion criteria included a serum triglyceride level
350 mg/dl; uncontrolled heart failure; recent (6 months)
myocardial infarction (MI); severe or unstable angina pec-
toris; hypothyroidism/hyperthyroidism or other endocrine
diseases; secondary hyperlipidemia; uncontrolled diabetes
mellitus; uncontrolled hypertension; heavy drinking; obese
patients on weight reduction programs; diseases that might
interfere with drug absorption; any severe illness; and
treatment with certain drugs, including corticosteroids,
other lipid-lowering agents or antacids containing alumi-
num salts. Written, informed consent was obtained from
each patient, and the trial was approved by the Ethics
Committee of Kyushu University Hospital.
Study design. Patients were randomly assigned to one of
the following three groups: 1) a probucol group (n 82, age
41 to 80 years) that received probucol at 500 mg twice daily
after meals; 2) a pravastatin group (n  83, age 41 to 89
years) that received pravastatin at 10 mg/day after the
evening meal; and 3) a control group (n  81, age 30 to 89
years) that was on diet alone. Randomization was done by
the minimization method, controlling for the following four
factors: total cholesterol level, age, gender and IMT. Hos-
pital visits for monitoring were scheduled after two weeks
and every four weeks thereafter. At each visit, a brief
physical examination was done, and the number of tablets
was counted to assess compliance. Measurement of lipids,
lipoproteins and safety laboratory variables was also done at
each visit. Thirty-four (21%) of the 165 patients in the
intent-to-treat population did not complete the study.
DEFINITION OF END POINTS. The primary end point was
the rate of progression of carotid atherosclerosis, which was
measured as the slope of the change in the mean IMT of six
carotid segments (3 sites each in the left and right common
carotid arteries, which were 2, 2.5 and 3 cm proximal to the
carotid bifurcation) on ultrasound examination. An increase
in IMT over two years was defined as “progression” and a
decrease in IMT over the same period was defined as
“regression.” Ultrasonography was performed at enrollment
and then every six months for the next 24 months. The
secondary end point was the incidence of major atheroscle-
rotic events, as effected by each treatment.
CLINICAL EVENTS. Clinical cardiac, cerebrovascular and
peripheral vascular events, as well as deaths, were moni-
tored. The time until the first cardiac event (coronary
angioplasty, coronary artery bypass graft surgery, definite or
probable MI or unstable angina pectoris requiring hospital
admission) and the time until death from any cause were
determined.
B-MODE ULTRASONOGRAPHY. The procedure used for
measuring carotid artery IMT, as well as its reproducibility,
has been described elsewhere (14). In brief, ultrasonography
was performed with the patient in the supine position, using
an Aloka SSD-2000 system (Aloka, Tokyo, Japan) with a
7.5-MHz transducer. All examinations were performed by
one trained physician who had no knowledge of the clinical
history and risk factor profile of the subjects. The IMT of
the far wall of the carotid artery was measured at 2, 2.5 and
3 cm proximal to the carotid bifurcation in each of the right
and left common carotid arteries. Measurements were made
on longitudinal scans obtained in the anterior oblique,
lateral and posterior oblique views. The IMT was defined as
the distance between two echogenic lines separated by a
hypoechoic or anechoic space, with the outer line corre-
sponding to the media-adventitia border and the inner line
representing the lumen-intima border. The mean IMT was
calculated as the average value of the IMT measurements
for the six sites in the carotid arteries. Stenosis was defined
as plaque (a site where IMT was 1.10 mm) occupying
more than half of the luminal circumference of the artery on
a transverse scan. A three-lead electrocardiogram was re-
corded simultaneously, and videotape recording of the
examination was done continuously. Images of each of the
IMT measurement sites were recorded on super VHS
videotape for subsequent off-line analysis.
Abbreviations and Acronyms
CETP  cholesterol ester transfer protein
CHD  coronary heart disease
HDL  high-density lipoprotein
IMT  intima-media thickness
LDL  low-density lipoprotein
MI  myocardial infarction
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Laboratory tests. Blood samples were collected between 8
and 9 AM after a 12-h fast. Serum cholesterol and triglyc-
eride levels were measured enzymatically. High-density
lipoprotein cholesterol was measured in the supernatant
after precipitation of apolipoprotein B–containing lipopro-
teins, according to the calcium heparin method, and LDL
cholesterol was computed using Friedewald’s formula (15).
All measurements were made on the day of blood collection,
in which case the blood was stored for no longer than three
days at 4°C until assay.
Statistical analysis. All data were recorded on standard-
ized forms and were entered into a data base. Results are
expressed as a percentage or mean value  SD. Differences
in frequencies were compared using the chi-square test, as
appropriate. Comparison of median values between more
than two groups was done by the nonparametric Krusal-
Wallis test. Differences between serum lipid levels at base-
line and after 6, 12, 18 and 24 months were compared using
Friedman’s test, with the Bonferroni correction for multiple
comparisons.
The primary end point of this study was the change in
IMT (mm) after 24 months. Differences in IMT among the
three groups were evaluated by the nonparametric Krusal-
Wallis test. Multiple comparisons of IMT changes at
various times of measurement were evaluated with the
Bonferroni correction. Forward stepwise multiple linear
regression analysis was performed to detect factors that
influenced the rate of change in IMT, and differences in
serum lipids levels from baseline were analyzed and selected
as variables for entry into the model by the forward stepwise
method. Correlations between the percent reduction in
IMT increase and LDL or HDL cholesterol level after two
years of treatment were evaluated by calculating Spearman’s
correlation coefficients.
The secondary end point was the incidence of major
atherosclerotic events, as effected by each treatment. Differ-
ences between the three groups were assessed by the
log-rank test, with the Bonferroni correction for multiple
comparisons. A p value 0.05 was considered statistically
significant in all analyses. All data were analyzed on an
intent-to-treat basis.
RESULTS
Baseline characteristics. The baseline characteristics of
the subjects are summarized in Table 1. The mean age of
the patients was 66.1 years, and 31.3% were men. Average
systolic and diastolic blood pressures were 130.8 and 77.1
mm Hg, respectively. Of the 246 patients, 146 (59.3%) were
recent or former smokers, 102 (41.5%) had a history of
hypertension and 56 (22.8%) had diabetes mellitus. Baseline
serum total cholesterol and LDL cholesterol levels were
253.0 and 166.1 mg/dl, respectively. The HDL cholesterol
and serum triglyceride levels were 57.0 and 149.2 mg/dl,
respectively. The mean IMT was 1.308 mm. There were no
statistically significant differences in any of these baseline
characteristics among the three groups.
Drug treatment and serum lipids. The changes in total
cholesterol, LDL cholesterol, HDL cholesterol and triglyc-
erides are shown in Figure 1.
TOTAL CHOLESTEROL. There was a significant decrease in
the serum total cholesterol level after 12 months of thera-
py—by 20.0% in the probucol group and by 20.1% in the
pravastatin group (both p  0.001 by Friedman’s test).
After 24 months of therapy, there was a further decrease in
both groups—24.1% and 23.0% total reductions, respec-
tively, when compared with baseline (both p  0.00l;
Friedman’s test). In the control group, the total cholesterol
Table 1. Baseline Characteristics of the Study Group
Total
(n  246)
Probucol Group
(n  82)
Pravastatin Group
(n  83)
Control Group
(n  81)
Age (years) 66.1  13.7 65.7  12.9 65.6  14.8 67.1  13.4
Men (%) 77 (31.3) 25 (30.4) 22 (26.5) 30 (37.0)
Blood pressure (mm Hg)
Systolic 130.8  21.9 132.2  22.7 129.2  22.7 130.9  20.2
Diastolic 77.1  11.4 77.8  13.0 75.6  11.2 77.8  9.6
Body mass index (kg/m2) 23.2  3.9 23.5  4.2 23.5  4.4 22.9  2.7
Smoking (%)
Recent or former 146 (59.3) 48 (58.5) 44 (53.0) 54 (66.7)
Never 100 (40.7) 34 (41.6) 39 (47.0) 27 (33.3)
History (%)
Hypertension 102 (41.5) 37 (45.1) 39 (47.0) 26 (32.1)
Diabetes 56 (22.8) 15 (18.3) 18 (21.7) 23 (28.4)
Cerebral vessel disease 103 (41.9) 35 (42.7) 34 (41.0) 34 (42.0)
Coronary heart disease 35 (14.2) 9 (11.0) 15 (18.1) 11 (13.6)
Serum cholesterol (mg/dl)
Total 253.0  26.3 252.4  25.6 251.5  24.8 255.2  28.4
Low-density lipoprotein 166.1  31.2 166.0  27.0 160.7  31.6 171.6  33.9
High-density lipoprotein 57.0  16.6 57.8  19.1 56.7  15.6 56.5  15.0
Serum triglycerides (mg/dl) 149.2  72.6 142.7  67.9 168.7  84.6 135.8  59.1
Intima-media thickness (mm) 1.308  0.597 1.347  0.642 1.267  0.642 1.286  0.501
Data are presented as the mean value  SD or number (%) of patients.
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level was reduced at the end of the study, but the difference
was not significant.
LOW-DENSITY LIPOPROTEIN CHOLESTEROL. Serum LDL
cholesterol levels were also reduced after 12 months, falling
by 24.2% in the probucol group (p  0.001 by Friedman’s
test), by 32.7% in the pravastatin group (p  0.001 by
Friedman’s test) and by 5.1% in the control group. After 24
months, there was a further decrease in all three groups,
with a decline of 28.6%, 35.9% and 8.5%, respectively, when
compared with baseline (p 0.00l, p 0.001 and p 0.05,
respectively, by Friedman’s test).
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL. The serum
HDL cholesterol level of the pravastatin group was in-
creased significantly (by 6.4%) after 24 months (p 0.05 by
Friedman’s test). In the control group, HDL cholesterol
also increased between baseline and 24 months (by 5.4%),
but the change was not significant. In contrast, the HDL
cholesterol level of the probucol group was significantly
reduced after 6 months (21.8%; p  0.00l by Friedman’s
test) and after 24 months (20.7%; p  0.05 by Friedman’s
test).
TRIGLYCERIDES. Triglyceride levels showed no significant
changes throughout the course of the study.
Intima-media thickness. The IMT changes in the probu-
col, pravastatin and control groups are shown in Figure 2. In
the probucol group, IMT was significantly reduced after 12
months of therapy (8.3%; p  0.01 by Friedman’s test).
After 24 months of therapy, there was a further significant
reduction, for a total reduction of 13.9%, compared with
baseline (p  0.0l by Friedman’s test). No significant
reduction in IMT was found during the first 18 months of
Figure 1. Serum lipid levels in the probucol (triangles), pravastatin (squares) and control (circles) groups. Data are presented as the mean value  SD.
*p  0.05; ***p  0.001 vs. baseline.
Figure 2. Changes in intima-media thickness (IMT) in the probucol
(triangles), pravastatin (squares) and control (circles) groups. Data are
presented as the mean value  SD. *p  0.05; **p  0.01 vs. baseline.
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therapy in the pravastatin group, but there was a significant
reduction by 13.9% after 24 months (p  0.01 by Friedman’s
test). In the control group, IMT increased significantly by
23.3% after 24 months (p  0.05 by Friedman’s test). The
change in IMT was significantly greater in the probucol and
pravastatin groups than in the control group (both p  0.001
by the Kruskal-Wallis test). There was no significant
difference in the change in IMT between the probucol and
pravastatin groups at 24 weeks after the end of treatment.
Multiple regression analysis of the reduction in IMT.
Forward stepwise multiple linear regression analysis was
performed to assess the factors influencing IMT regression.
Lipid-lowering therapy was found to be the most important
independent factor associated with the rate of IMT regres-
sion (F  13.60, p  0.0001). The reduction of LDL
cholesterol after two years of treatment was also indepen-
dently associated with the rate of IMT regression (F 
12.28, p 0.0007). In contrast, age showed an independent
association with the rate of IMT progression (F  11.53, p
 0.0009). There were no significant associations between
IMT changes and any of the other variables investigated.
Correlation between percent reduction in IMT progres-
sion and LDL cholesterol. There was a weak but signif-
icant and positive correlation between the absolute change
in IMT and the change in LDL cholesterol in the prava-
statin group (r  0.363, p  0.0051 by Spearman’s
method), but there was no such correlation in the probucol
or control group (r  0.065, p  0.5892 and r  0.130, p
 0.3321, respectively, by Spearman’s method). There was
no correlation between the absolute change in IMT and the
change in HDL cholesterol in any of the groups.
Cumulative incidence of major cardiovascular events and
mortality. Among the 82 patients in the probucol group,
two had a major cardiovascular event (2 died of CHD),
compared with 4 of the 83 patients in the pravastatin group
(3 died of CHD and 1 had a nonfatal MI) and 11 of the 81
patients in the control group (8 died of CHD and 3 had a
nonfatal MI) (Table 2, Fig. 3). Of the 16 deaths that
occurred during this study, two were in the probucol group,
5 were in the pravastatin group and 9 were in the control
group. Among these 16 deaths, 13 were from cardiovascular
causes, whereas the others were from gastrointestinal bleed-
ing and infection. There was a significantly lower incidence
of cardiac events in the probucol group than in the control
group (p  0.05 by the log-rank test). There was also a
lower incidence of death in the probucol group than in the
control group, but the difference was not significant.
DISCUSSION
The present study adds new information to the ever-
growing pool of data on anti-atherogenic regimens. The
Fukuoka AtheroSclerosis Trial (FAST) is the first study to
demonstrate the benefit of probucol in patients with hyper-
cholesterolemia and also to demonstrate an effect of probu-
col on the incidence of cardiovascular disease.
Probucol is among the most extensively used lipid-
lowering drugs and has been associated with many poten-
tially beneficial outcomes. Despite this, probucol therapy
lost some credibility after the apparently negative findings of
the Probucol Quantitative Regression Swedish Trial
(PQRST) (16). The changes in IMT in our probucol group
are in striking contrast to those reported in PQRST, in
which the target vessel was the femoral artery. However,
reports of IMT regression in the femoral artery are limited,
and the arterial caliber monitoring method used in PQRST
could potentially be influenced by arterial remodeling (17).
Table 2. Serious Adverse Events Reported During the Two-Year Follow-Up Period
Clinical Event
Probucol Group
(n  82)
Pravastatin Group
(n  83)
Control Group
(n  81)
Total cardiovascular events 2 (2.4%) 4 (4.8%) 11 (13.6%)
Fatal MI 2 (2.4%) 3 (3.6%) 8 (9.9%)
Nonfatal MI 0 1 (1.2%) 3 (3.7%)
PTCA/CABG 0 1 (1.2%) 0
Total cerebrovascular events 0 0 0
Total other events 0 2 (2.4%) 1 (1.2%)
Total deaths 1 (2.4%) 5 (6.0%) 9 (11.1%)
Data are presented as the number (%) of patients.
CABG  coronary artery bypass graft surgery; MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty.
Figure 3. Kaplan-Meier estimates of the occurrence of all coronary events.
Bold solid line  control group; thin solid line  pravastatin group;
broken line  probucol group. There was a significant difference between
the control group and probucol groups (*p  0.05 by the log-rank test).
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B-mode ultrasonography. The B-mode ultrasonography
modality used in this study is an attractive tool for assessing
the effect of drugs on atherosclerosis. The amount of data
obtained by this method is growing through a number of
other clinical trials now in progress. Moreover, increasingly
precise estimates of the progression rate under various
clinical conditions and the effect of treatment on progres-
sion have become available (16). This may be because
cardiovascular events influence the vessel wall rather than
the lumen and because the association between arterial IMT
and the lumen diameter is imprecise (17). In support of this
view, we found that the IMT progression in the common
carotid artery was significantly reduced in the probucol and
pravastatin groups, but not in the control group. The
changes in carotid artery IMT in the pravastatin group
resembled those reported previously (6,7).
Lipid-lowering effect. Evidence from epidemiologic and
clinical studies has demonstrated that LDL cholesterol is a
key element in the development of atherosclerosis, and that
reducing LDL cholesterol levels leads to a lower risk of
CHD. Recent studies using pravastatin have demonstrated
a substantial reduction in cholesterol, along with a signifi-
cant reduction in coronary and all-cause mortality (18). The
three groups in this study showed a substantial reduction in
the LDL cholesterol level. We found the reduction in LDL
cholesterol to be more significant in the pravastatin than in
the probucol and control groups. Although the control
group showed a significant reduction of LDL cholesterol by
diet alone, progression of IMT still occurred, unlike the
outcome in the active treatment groups. This suggests that
life-style modification alone did not adequately retard IMT
progression.
Another mechanism of the anti-atherogenic effect of
probucol. Our study revealed that probucol not only re-
duced the LDL level, but also caused a decrease in HDL
cholesterol. This reduction in HDL cholesterol by probucol
may reflect an increase in reverse cholesterol transport, most
likely resulting from the direct induction of cholesterol ester
transfer protein (CETP), consequently having an anti-
atherogenic effect (19), because probucol has been reported
to enhance reverse cholesterol transport from the periphery
to the liver by HDL (20), and this activity appears to be
dependent on increased CETP activity (19). However,
probucol therapy retarded the progression of IMT, inde-
pendent of its LDL or HDL cholesterol-lowering effect in
the present study. Moreover, the IMT reduction occurred
earlier with probucol than with pravastatin. These findings
suggest that there may be another mechanism involved in
the effect on IMT progression that is independent of the
lipid-lowering effect of probucol.
Stabilization of plaque. Numerous pathophysiologic ob-
servations in humans and animals have led to the response-
to-injury hypothesis of atherosclerosis, which emphasizes
endothelial dysfunction as the first step in the atheroscle-
rotic process. Endothelial dysfunction is possibly related to
an increase of LDL and modified LDL, genetic alterations,
elevation of plasma homocysteine or infection with micro-
organisms, or a combination of these or other factors (21).
The atherosclerotic process leads to the enlargement of
vulnerable plaques, which are characterized by a lipid-rich
core and a thin fibrous cap. The advanced stages are
associated with accumulation of monocytes and lympho-
cytes, platelet adhesion and apoptosis. Cardiac events, such
as acute coronary syndromes (e.g., unstable angina and MI),
appear to result from plaque rupture (22). Probucol has also
been shown to modify vascular remodeling after balloon
angioplasty, and remodeling is an important component of
the restenotic process (23). In addition, probucol has a
radical-scavenging effect and inhibits the production of
platelet-derived growth factor and interleukin-1, giving it
an anti-inflammatory effect (24). Such reports suggest that
probucol may not only have a lipid-lowering effect, but may
also stabilize plaque. Interestingly, the present study dem-
onstrates that the incidence of cardiac events was lower in
the probucol group than in the control or pravastatin group.
Study limitations. Because the sample size was small in the
present study, a difference in the effects of probucol and
pravastatin on IMT could not be demonstrated. Therefore,
a large-scale investigation will be necessary to determine
whether probucol and pravastatin show any differences in
their effect on IMT. The lack of a placebo control group was
another limitation. However, the use of quantitative
B-mode ultrasonography allowed us to obtain unbiased
data.
Conclusions. Probucol was effective in reducing the cho-
lesterol level and stabilizing plaque in hypercholesterolemic
patients, which probably explains a reduction in the inci-
dence of cardiac events.
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